Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective.
Journal
Journal of the advanced practitioner in oncology
ISSN: 2150-0878
Titre abrégé: J Adv Pract Oncol
Pays: United States
ID NLM: 101550346
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
At the opening session of JADPRO Live Virtual 2021, panelists shared creative responses to the COVID-19 pandemic and considered strategies to effectively respond to crises that may impact cancer patients and practices in the future.
Identifiants
pubmed: 35663159
doi: 10.6004/jadpro.2022.13.3.2
pii: 2022.13.3.2
pmc: PMC9126341
doi:
Types de publication
Journal Article
Langues
eng
Pagination
198-201Informations de copyright
© 2022 Harborside™.
Déclaration de conflit d'intérêts
Dr. Harvey has served as a consultant to Amgen and GlaxoSmithKline and has received institutional research funding from Abbisko Therapeutics, AbbVie, Actuate, Alkermes, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Biomedical, Calithera, FujiFilm, Genmab, GlaxoSmithKline, Infinity, InhibRx, Janssen, Lycera, Merck, Mersana, Meryx, Nektar, Pfizer, Puma Biotechnology, Rapt Therapeutics, Regeneron, Rgenix, Sanofi, Seattle Genetics, Sutro, Takeda, and Xencor. Mr. Begue and Mr. Raine have no conflicts of interest to disclose. Dr. Yabroff has served on the health equity advisory board of Flatiron Health.
Références
J Natl Cancer Inst. 2022 Jun 13;114(6):907-909
pubmed: 34181001